MA-HAMAMATSU-PHOTONICS
10.6.2019 05:02:05 CEST | Business Wire | Press release
Hamamatsu Photonics K.K. (TOKYO:6965) has developed a novel 3D fluorescence scanning method called “Zyncscan™” that performs x-z plane scans using a light-sheet for cell-based fluorescence assays in microplates. This technology provides an x-z plane scan using a light-sheet for a whole 96/384/1536-well microplate, allowing users to obtain 3D fluorescence images of whole wells in xy: 2-3 μm and z: 6-7 μm voxel resolution for ≤ 300 μm thickness from the well bottom within a few minutes per color. This technology also allows for ultra-high level separation of cell fluorescence signals from the background, which makes it possible to obtain fluorescence cell images in the cell culture mediums containing serum and with fluorescent dyes (i.e., no need to wash out fluorescent dyes).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005009/en/
Background of development
In drug discovery and development, there is a rapidly growing need to use more physiologically-relevant in vitro cell culture models. These include primary cells, patient-derived cells, human iPSC-derived disease-modeling cells, co-cultures of different types of cells, and 3D cultures such as spheroids and organoids. To develop and advance phenotypic assays and screenings using these physiologically-relevant cellular models, new types of instruments needed to be developed to facilitate high-throughput fluorescence imaging and measurement of heterogeneous 2D and 3D cell cultures. To meet this need, we have developed ZyncscanTM technology that performs an x-z plane scan utilizing a light-sheet for a microplate.
Features of the cell-based fluorescence assays in microplate using Zyncscan™ technology
| 1) | High-speed fluorescence cytometry for 2D monolayer heterogeneous cell culture | |
| A single 120-second scan (one color) for a whole 96/384/1536-well microplate enables fluorescence cytometry of all individual cells in all wells. | ||
| 2) | Single spheroid analyses using depth information (diameter of spheroid; ≤ 200 μm) | |
| A single scan (in just a few minutes) for a microplate enables fluorescence images of spheroids (single or multiple spheroids in a well) in all wells in a 96/384/1536-well microplate. From the images, the entire fluorescence intensity, thickness and volume of each individual spheroid are estimated. | ||
| 3) | Fluorescence images in 3D view (≤ 300 μm) | |
| With a single scan (a few minutes) obtain 3D fluorescence images (300 μm from the bottom of a well) of all wells in a plate. The optical resolution of the image is comparable with the 2x objective of a conventional fluorescence microscope in the x- and y-axes and a 10x objective of confocal fluorescence microscope in the z-axis. | ||
| 4) | In-medium / No dye washout measurement | |
| Measure cellular fluorescence in the medium containing serum and with fluorescent dyes (no need to wash out fluorescent dyes), allowing cells to remain healthy throughout the experiment. | ||
Future outlook
Hamamatsu Photonics K.K. has been developing a fluorescence instrument for cell-based assays equipped with Zyncscan™ technology, CYTOQUBE™, a Light-Sheet Microplate Cytometer. We plan to initiate validation and application experiments in several research sites in drug discovery and development by early 2020. CYTOQUBE™ is planned to be released by the end of the next fiscal year (September 2020).
We will showcase a prototype of the CYTOQUBE™ (Light-Sheet Microplate Cytometer) at the following conferences.
| WPC (World Preclinical Congress) |
| June 17-20, 2019, Boston, MA, USA |
| CYTO |
| June 22-26, 2019, Vancouver, BC, Canada |
Please visit here for more detailed information.
https://www.hamamatsu.com/all/en/news/featured-products_technologies/2019/20190610000000.html
Hamamatsu Photonics K.K.
Hamamatsu Photonics K.K. is a leading manufacturer of photonics devices. We design, manufacture, and sell optical sensors, light sources, optical components, cameras, photometry systems, and measurement/analysis systems.
Web site
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005009/en/
Contact:
Technical Contacts details Hamamatsu Photonics K.K, System Division Business Promotion Department 812, Joko-cho, Higashi-ku, Hamamatsu City, 431-3196 Japan email: export@sys.hpk.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom